Aldeyra Therapeutics (ALDX) Other Non-Current Assets (2022 - 2023)
Aldeyra Therapeutics (ALDX) posted Other Non-Current Assets of $1.0 million for Q4 2023, up 195.73% on a QoQ basis from $342210.0 in Q4 2022, and up 195.73% year-over-year from $342210.0 in Q4 2022.
Aldeyra Therapeutics (ALDX) Other Non-Current Assets (2022 - 2023) Analysis & Trends
Aldeyra Therapeutics' Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2023.
- Quarterly Other Non-Current Assets rose 195.73% year-over-year to $1.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.0 million (up 195.73% YoY) and the FY2023 annual result came in at $1.0 million, up 195.73% from the prior year.
- Other Non-Current Assets was $1.0 million for Q4 2023 at Aldeyra Therapeutics, up from $342210.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $1.0 million in Q4 2023 and bottomed at $342210.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 60,000.00 |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 104.24 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Aldeyra Therapeutics | 93.19 Mn | 93.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.01 Mn |
| Dec 31, 2022 | 342,210.00 |